DEX vs SEVO in Congenital Heart Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT05369949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05369949
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05369949. Randomized; no masking; primary purpose treatment. Start 2023-01-05 (anticipated); primary completion 2025-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DEX vs SEVO in Congenital Heart Surgery
Acronym
DEXLOSNeuro
Condition
Heart Defects, Congenital
Intervention (Drug)
DEX group
Intervention (Other)
Control group
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain (class: other)

Record details

Record id
cardio:ct-nct05369949
Content hash
6872ac575a8ffaf506fad51c2876aaa7093d325c4a7d294c28d1ab69a0fa73dc